Regeneron Pharmaceuticals, Inc. $REGN Stock Sold by Modera Wealth Management LLC

Modera Wealth Management LLC reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,962 shares of the biopharmaceutical company’s stock after selling 720 shares during the quarter. Modera Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $4,521,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of REGN. LCM Capital Management Inc grew its stake in Regeneron Pharmaceuticals by 2.2% in the 3rd quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock worth $467,000 after buying an additional 13 shares in the last quarter. Arjuna Capital raised its position in shares of Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 14 shares in the last quarter. Oakworth Capital Inc. raised its position in shares of Regeneron Pharmaceuticals by 25.0% during the 3rd quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 14 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 1.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock worth $645,000 after acquiring an additional 15 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 16 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research analyst reports. Robert W. Baird increased their target price on Regeneron Pharmaceuticals from $742.00 to $761.00 and gave the company a “neutral” rating in a research note on Friday, July 31st. Canaccord Genuity Group lifted their price target on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a research note on Wednesday. Truist Financial lifted their price target on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Zacks Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Finally, JPMorgan Chase & Co. increased their price objective on Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a research report on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $850.83.

Insider Buying and Selling

In related news, EVP Marion Mccourt sold 1,131 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the transaction, the executive vice president directly owned 12,003 shares in the company, valued at $10,291,252.17. This trade represents a 8.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the firm’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the transaction, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. The trade was a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 8,093 shares of company stock worth $6,506,845. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $927.89 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $95.54 billion, a PE ratio of 20.49, a P/E/G ratio of 1.57 and a beta of 0.16. The firm has a fifty day simple moving average of $793.30 and a two-hundred day simple moving average of $738.05. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $935.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $4.58 billion. During the same period in the prior year, the business posted $11.83 earnings per share. The company’s revenue was up 36.3% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current year.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations: Regeneron reported $5.12 billion in revenue, up 36.3% year over year and well above the approximately $4.56 billion analyst consensus. Non-GAAP EPS was $20.07, compared with estimates near $16.42 and $11.83 a year earlier. REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
• Positive Sentiment: Strong commercial performance: Sanofi-partnered Dupixent generated robust demand, while U.S. Eylea HD sales increased 62% to $699 million and global Libtayo sales rose 51% to $550 million. The results suggest Regeneron’s product portfolio is offsetting competitive and pricing pressures in older treatments. Regeneron Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: Pipeline and strategic momentum: Regeneron highlighted progress toward upcoming FDA catalysts, expanded its Sanofi collaboration with next-generation long-acting immunology antibodies and received a $1 billion upfront payment to be recognized as collaboration revenue. A new Phase 2 cemiplimab combination study also expands its skin-cancer pipeline. Regeneron Expands Skin Cancer Pipeline With New Cemiplimab Combo Trial
• Neutral Sentiment: Management characterized 2026 as potentially one of Regeneron’s strongest years, and analysts have raised some expectations following the earnings beat. Investors will now focus on whether Dupixent growth and new launches can remain durable.
• Negative Sentiment: Eylea 2 mg remains exposed to biosimilar competition, while at least one analyst recently lowered Regeneron’s price target from $900 to $850. After the sharp upward move, valuation and the need for continued execution could create near-term volatility. Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.